Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020229626 - DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY

Publication Number WO/2020/229626
Publication Date 19.11.2020
International Application No. PCT/EP2020/063529
International Filing Date 14.05.2020
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
Applicants
  • F-STAR DELTA LIMITED [GB]/[GB]
Inventors
  • MORROW, Michelle
  • GERMASCHEWSKI, Fiona
  • GLIDDON, Daniel
  • LEUNG, Kin-mei
  • GRADINARU, Cristian
  • SHEPHERD, Christopher
  • HOLZ, Josefin-Beate
  • KAYITALIRE, Louis
Agents
  • MEWBURN ELLIS LLP
Priority Data
1906807.114.05.2019GB
1914040.930.09.2019GB
2000318.209.01.2020GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY
(FR) RÉGIMES POSOLOGIQUES POUR L'ADMINISTRATION D'UN ANTICORPS BISPÉCIFIQUE DE LAG-3/PD-L1
Abstract
(EN)
The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
(FR)
L'invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie à la mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) et leur utilisation médicale dans le traitement du cancer chez des patients humains.
Latest bibliographic data on file with the International Bureau